Preliminary and Unaudited 2021 Financial Results
- Fourth quarter 2021 total revenue is expected to be in the range of
$14.5 million to$14.8 million , an estimated increase of 63% compared to the prior year period and a sequential increase of 12% compared to the third quarter.- Surgical Glaucoma revenues are expected to be in the range of
$13.8 million to$14.0 million , an estimated increase of 59% compared to the prior year period and a sequential increase of 12% compared to the third quarter. - Dry Eye revenues are expected to be in the range of
$0.7 million to$0.8 million , an estimated increase of 175% compared to the prior year period and a sequential increase of 14% compared to the third quarter.
- Surgical Glaucoma revenues are expected to be in the range of
- Full year 2021 total revenue is expected to be in the range of
$48.8 million to$49.1 million , an increase of 77% compared to the prior year.- Surgical Glaucoma revenues are expected to be in the range of
$46.4 million to$46.6 million , an estimated increase of 79% compared to the prior year. - Dry Eye revenues are expected to be in the range of
$2.4 million to$2.5 million , an estimated increase of 49% compared to the prior year.
- Surgical Glaucoma revenues are expected to be in the range of
“We are proud of the excellent performance from our entire organization throughout a very challenging yet rewarding year and are pleased with our record-setting performance across both of our business lines,” said
The Company’s fourth quarter and full year 2021 financial results are preliminary and are subject to the completion of the Company’s 2021 audit. Complete fourth quarter and full year 2021 financial results will be announced in March.
Financial Disclosure Advisory
The Company reports its financial results in accordance with
About
OMNI® and TearCare® are registered trademarks of
© 2022
Forward-Looking Statements
This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions. Any statements made in this press release or during the earnings call that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies. These statements often include words such as “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast” and other similar expressions. We base these forward-looking statements on our current expectations, plans and assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at such time. Although we believe that these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our business, results of operations and financial condition and could cause actual results to differ materially from those expressed in the forward-looking statements. These statements are not guarantees of future performance or results. The forward-looking statements are subject to and involve risks, uncertainties and assumptions, and you should not place undue reliance on these forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the following: estimates of our total addressable market, future revenue, expenses, capital requirements, and our needs for additional financing; our ability to enter into and compete in new markets; the impact of the COVID-19 pandemic on our business, our customers’ and suppliers’ businesses and the general economy; our ability to compete effectively with existing competitors and new market entrants; our ability to scale our infrastructure; our ability to manage and grow our business by expanding our sales to existing customers or introducing our products to new customers; our ability to establish and maintain intellectual property protection for our products or avoid claims of infringement; potential effects of extensive government regulation; our abilities to obtain and maintain regulatory approvals and clearances for our products that support our revenue projections, business strategies and growth; our ability to successfully execute our clinical trial roadmap; our ability to obtain and maintain sufficient reimbursement for our products; our abilities to protect and scale our intellectual property portfolio; our ability to hire and retain key personnel; our ability to obtain financing in future offerings; the volatility of the trading price of our common stock; our expectation regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act (the “JOBS Act”); our ability to maintain proper and effective internal controls; and the other important factors discussed under the caption “Risk Factors” in our filings with the
Media contact:
Health+Commerce
707.971.9779
shay@healthandcommerce.com
Investor contact:
415.937.5406
Investor.Relations@Sightsciences.com
Source:
2022 GlobeNewswire, Inc., source